Levetiracetam (All indications) updated on 04-22-2025

Maternal consequences (as a whole)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16570
R69625		 Razaz (Levetiracetam) (Epilepsy), 2024 Severe maternal morbidity (severe preeclampsia, severe hemorrhage, surgical complications, sepsis, obstetric shock, cardiac complications, kidney failure, cerebrovascular morbidity, complications of anesthesia and obstetric interventions and/or severe mental health conditions) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 1.27 [0.93;1.75] 45/1,009   656/19,043 701 1,009
ref
S12704
R47940		 Alsfouk (Levetiracetam), 2022 Maternal complication (bleeding during pregnancy, gestational hypertension, eclampsia, preeclampsia, gestational diabetes, cervical cerclage, placenta abruption, prolonged labor, pre-mature rupture of membranes, seizure on day of delivery or during delivery, and post-partum hemorrhage) during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No 1.33 [0.28;6.39] C 6/24   3/15 9 24
ref
Total 2 studies 1.27 [0.93;1.73] 710 1,033
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Razaz (Levetiracetam) (Epilepsy), 2024Razaz, 2024 1 1.27[0.93; 1.75]7011,00996%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Alsfouk (Levetiracetam), 2022Alsfouk, 2022 2 1.33[0.28; 6.39]9244%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.27[0.93; 1.73]7101,0330.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam) (Epilepsy; 2: Levetiracetam;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.27[0.93; 1.73]7101,0330%NARazaz (Levetiracetam) (Epilepsy), 2024 Alsfouk (Levetiracetam), 2022 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.27[0.93; 1.74]7011,009 -NARazaz (Levetiracetam) (Epilepsy), 2024 1 exposed to other treatment, sickexposed to other treatment, sick 1.33[0.28; 6.39]924 -NAAlsfouk (Levetiracetam), 2022 1 Tags Adjustment   - No  - No 1.33[0.28; 6.39]924 -NAAlsfouk (Levetiracetam), 2022 1   - Yes  - Yes 1.27[0.93; 1.74]7011,009 -NARazaz (Levetiracetam) (Epilepsy), 2024 1 All studiesAll studies 1.27[0.93; 1.73]7101,0330%NARazaz (Levetiracetam) (Epilepsy), 2024 Alsfouk (Levetiracetam), 2022 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.27[0.93; 1.74]7011,009 -NARazaz (Levetiracetam) (Epilepsy), 2024 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.33[0.28; 6.39]924 -NAAlsfouk (Levetiracetam), 2022 10.510.01.0